Rapport Therapeutics, Inc. (RAPP)
RAPP moved a median of +0.21% 30 minutes after news, and -0.13% by the close. How RAPP actually reacts to news — the realized, point-in-time move the market made, measured across 235 labeled events over the last three years with zero look-ahead.
RAPP’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.05% | 51% | 232 |
| 30-min | +0.21% | 53% | 235 |
| 60-min | +0.10% | 52% | 235 |
| to close | -0.13% | 50% | 234 |
| Middle 50% of RAPP reactions | -0.98% to +2.53% |
|---|---|
| Median reaction (30-min) | +0.21% |
| Measured reactions | 235 |
Half of all Rapport Therapeutics, Inc. news events land between -0.98% and +2.53% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How RAPP reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 37 | -0.51% | 24% | -2.32% |
| Rating reiterations | 31 | -0.16% | 48% | -1.07% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how RAPP ranks against every other measured name →
That’s how RAPP usually reacts — get an email when it moves on news →Email me when RAPP moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to RAPP's baseline. Nothing else.
Recent RAPP events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Rapport Therapeutics to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +2.39% | +0.39% | |
| Rapport Therapeutics to Host Virtual KOL Event on the Unmet Need in Bipolar Mania and the RAP-219 Clinical Program | Press release | GlobeNewswire | +1.10% | +2.43% | |
| Form 10-Q Rapport Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +2.51% | +2.44% | |
| Form 8-K Rapport Therapeutics, For: Aug 05 | SEC filing · Form 8-K | SEC EDGAR | +2.51% | +2.44% | |
| Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update | Press release | GlobeNewswire | +2.51% | +2.44% | |
| Form 8-K Rapport Therapeutics, For: Jun 10 | SEC filing · Form 8-K | SEC EDGAR | -0.17% | +0.09% | |
| Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference | Press release | GlobeNewswire | +0.41% | +2.86% | |
| Form 10-Q Rapport Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -1.84% | +6.42% | |
| Form 8-K Rapport Therapeutics, For: May 07 | SEC filing · Form 8-K | SEC EDGAR | -1.84% | +6.42% | |
| Rapport Therapeutics Reports First Quarter 2026 Financials and Provides Business Update | Press release | GlobeNewswire | -1.84% | +6.42% | |
| Form ARS Rapport Therapeutics, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -3.02% | -1.14% | |
| Form DEF 14A Rapport Therapeutics, For: Jun 10 | SEC filing · Form DEF | SEC EDGAR | -3.02% | -1.14% | |
| Form DEFA14A Rapport Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | -3.02% | -1.14% | |
| Form 8-K Rapport Therapeutics, For: Apr 21 | SEC filing · Form 8-K | SEC EDGAR | -1.00% | -1.60% | |
| Rapport Therapeutics Presents RAP-219 Focal Onset Seizure Phase 2a Follow-up Period Results Demonstrating Sustained Seizure Reduction at the 2026 American Academy of Neurology Annual Meeting | Press release | GlobeNewswire | -1.00% | -1.60% | |
| Rapport Therapeutics to Present New Phase 2 Treatment Follow-Up Data for RAP-219 in Focal Onset Seizures at the 2026 American Academy of Neurology Annual Meeting | Press release | GlobeNewswire | +0.89% | +0.86% | |
| Form 10-K Rapport Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -0.69% | +1.47% | |
| Form 8-K Rapport Therapeutics, For: Mar 10 | SEC filing · Form 8-K | SEC EDGAR | -0.69% | +1.47% | |
| Form S-3ASR Rapport Therapeutics, | SEC filing · Form S-3ASR | SEC EDGAR | -0.69% | +1.47% | |
| Form S-8 Rapport Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | -0.69% | +1.47% | |
| Rapport Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | -0.69% | +1.47% | |
| Rapport Therapeutics and Tenacia Biotechnology Announce Strategic Collaboration for the Development and Commercialization of RAP-219 in Greater China | Press release | GlobeNewswire | +5.30% | +0.63% | |
| Rapport Therapeutics to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | -0.61% | +3.04% | |
| Form 8-K Rapport Therapeutics, For: Jan 07 | SEC filing · Form 8-K | SEC EDGAR | -0.59% | +8.89% | |
| Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Phase 3 Program, Expansion of Epilepsy Portfolio, and Continued Progress Across the Pipeline | Press release | GlobeNewswire | -0.59% | +8.89% | |
| Rapport Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference | Press release | GlobeNewswire | +0.38% | +1.40% | |
| Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219’s Clinical Response in Patients with Focal Onset Seizures | Press release | GlobeNewswire | +0.15% | +1.72% | |
| Rapport Therapeutics to Present New Phase 2a Data Analysis Further Characterizing RAP-219 in Focal Onset Seizures at 2025 American Epilepsy Society Annual Meeting | Press release | GlobeNewswire | +2.09% | +1.42% | |
| Form 10-Q Rapport Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.38% | -4.30% | |
| Form 8-K Rapport Therapeutics, For: Nov 06 | SEC filing · Form 8-K | SEC EDGAR | -0.38% | -4.30% | |
| Rapport Therapeutics Reports Third Quarter 2025 Financials and Provides Business Update | Press release | GlobeNewswire | -0.38% | -4.30% | |
| Rapport Therapeutics to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | -0.38% | -4.30% | |
| Rapport Therapeutics to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit | Press release | GlobeNewswire | +0.04% | -2.02% | |
| Form 8-K Rapport Therapeutics, For: Sep 09 | SEC filing · Form 8-K | SEC EDGAR | +1.66% | +3.80% | |
| Rapport Announces Pricing of Public Offering of Common Stock | Press release | GlobeNewswire | -1.06% | -7.01% | |
| Form 8-K Rapport Therapeutics, For: Sep 08 | SEC filing · Form 8-K | SEC EDGAR | +2.22% | -17.90% | |
| Rapport Announces Positive Topline Results from Phase 2a Clinical Trial of RAP-219 in Patients with Focal Onset Seizures | Press release | GlobeNewswire | +2.22% | -17.90% | |
| Rapport Announces Proposed Public Offering of Common Stock | Press release | GlobeNewswire | -3.40% | -12.19% | |
| Rapport Therapeutics to Announce Topline Results for RAP-219 Phase 2a Trial in Focal Onset Seizures on Monday, September 8, 2025 | Press release | GlobeNewswire | +2.22% | -17.90% | |
| Form 10-Q Rapport Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | +5.48% | |
| Form 8-K Rapport Therapeutics, For: Aug 07 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +5.48% | |
| Rapport Therapeutics Reports Second Quarter 2025 Financials and Provides Business Update | Press release | GlobeNewswire | +0.00% | +5.48% | |
| Form EFFECT Rapport Therapeutics, | SEC filing · Form EFFECT | SEC EDGAR | +1.07% | +9.54% | |
| Form S-3 Rapport Therapeutics, | SEC filing · Form S-3 | SEC EDGAR | +2.26% | +2.35% | |
| Form 8-K Rapport Therapeutics, For: Jun 17 | SEC filing · Form 8-K | SEC EDGAR | +1.71% | -1.62% | |
| Form 8-K Rapport Therapeutics, For: Jun 02 | SEC filing · Form 8-K | SEC EDGAR | -2.13% | +26.97% | |
| Rapport Therapeutics Hosts Investor and Analyst Day; Provides Corporate Updates | Press release | GlobeNewswire | +0.11% | +1.79% | |
| Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 46th Annual Global Healthcare Conference | Press release | GlobeNewswire | -0.36% | -8.89% | |
| Rapport Therapeutics to Host 2025 Investor and Analyst Day | Press release | GlobeNewswire | +3.02% | -2.14% | |
| Form 10-Q Rapport Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | +4.21% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the RAPP section they belong to.
Where else RAPP is measured.
RAPP earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Rapport Therapeutics, Inc.'s median reaction calculated?
Every labeled RAPP news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 235 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 53% of RAPP's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does RAPP's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.